Staar Surgical
STAA
22.31
-0.05
-0.22%
Staar Surgical
US · STAA
#3168 by market cap
22.31
-0.05
-0.22%
Live - 5344 symbols - heartbeat 150s ago
· 2026-10-08 10:10
Pre-market
22.00
-1.61%
After-hours
22.36
0.00%
- Market cap
- 1.12B
- P/E (TTM)i
- 278.88
- P/Bi
- 3.06
- EPSi
- -1.62
- Div yieldi
- 0.00%
- 52W posi
- 33%
Reader sentiment
Are you bullish or bearish on STAA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.63, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -23.72% YoY
Margins
- Gross margin
- 76.19%
- Operating margin
- -19.19%
- Net margin
- -33.60%
Key ratios & quality
- Altman Z-Scorei
- 6.63
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 123.95M | 150.19M | 163.46M | 230.47M | 284.39M | 322.42M | 313.90M | 239.44M |
| Gross profit | 91.51M | 111.95M | 118.36M | 178.64M | 223.38M | 252.65M | 239.58M | 182.42M |
| Selling & admin expenses | 62.89M | 74.80M | 79.68M | 111.44M | 143.60M | 184.08M | 206.88M | 188.31M |
| Research & development | 22.03M | 25.30M | 31.92M | 33.86M | 35.98M | 40.48M | 45.32M | 40.06M |
| Operating profit | 6.60M | 11.85M | 6.77M | 33.34M | 43.80M | 28.10M | -12.61M | -45.95M |
| Pretax profit | 6.64M | 13.03M | 8.27M | 31.30M | 45.55M | 33.70M | -9.05M | -82.26M |
| Tax | 1.67M | -1.02M | 2.35M | 3.79M | 5.89M | 12.35M | 11.16M | -1.82M |
| Net profit | 4.97M | 14.05M | 5.91M | 27.51M | 39.67M | 21.35M | -20.21M | -80.45M |
| Basic EPS | 0 | 0 | 0 | 1 | 1 | 0 | 0 | -2 |
| Diluted EPS | 0.11 | 0.30 | 0.12 | 0.56 | 0.80 | 0.43 | -0.41 | -1.62 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Revenue | 42.59M | 44.32M | 94.73M | 57.80M | 93.52M | 93.54M |
| Gross profit | 28.01M | 32.80M | 77.88M | 43.74M | 68.86M | 69.73M |
| Selling & admin expenses | 51.40M | 47.25M | 44.22M | 45.43M | 41.53M | 49.68M |
| Research & development | 11.34M | 10.26M | 9.21M | 9.24M | 9.93M | 9.94M |
| Operating profit | -34.74M | -24.72M | 24.44M | -10.94M | 17.40M | 10.10M |
| Pretax profit | -54.49M | -25.92M | 18.79M | -20.65M | 8.22M | 11.02M |
| Tax | -275.00K | -9.10M | 9.91M | -2.34M | 3.01M | 2.97M |
| Net profit | -54.21M | -16.81M | 8.88M | -18.31M | 5.21M | 8.06M |
| Basic EPS | -1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -1.10 | -0.34 | 0.18 | -0.37 | 0.10 | 0.16 |
Balance sheet
| Line item | 2018 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 151.57M | 174.67M | 216.42M | 271.41M | 311.72M | 365.27M | 367.94M | 311.55M |
| Cash & ST investments | 103.88M | 119.97M | 152.45M | 199.71M | 211.64M | 220.73M | 230.49M | 187.54M |
| Inventory | 16.70M | 17.14M | 18.11M | 17.27M | 24.16M | 35.13M | 43.31M | 55.50M |
| Total assets | 167.34M | 207.52M | 257.42M | 345.78M | 418.82M | 488.69M | 509.52M | 451.68M |
| Total current liabilities | 27.73M | 34.48M | 41.24M | 48.80M | 51.72M | 65.04M | 70.31M | 68.50M |
| Short-term debt | 4.88M | 5.09M | 4.22M | 3.41M | 3.69M | 4.37M | 3.94M | 5.87M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 34,913,000.00 | 47,639,000.00 | 60,194,000.00 | 87,220,000.00 | 82,706,000.00 | 102,738,000.00 | 112,189,000.00 | 107,494,000.00 |
| Total equity | 132.43M | 159.88M | 197.22M | 258.56M | 336.11M | 385.95M | 397.34M | 344.18M |
| Retained earnings | -156.28M | -141.80M | -135.89M | -111.39M | -68.72M | -47.37M | -67.58M | -148.02M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Total current assets | 326.50M | 292.79M | 321.21M | 311.55M | 312.40M | 342.35M |
| Cash & ST investments | 222.76M | 189.88M | 192.66M | 187.54M | 163.89M | 181.49M |
| Inventory | 48.14M | 53.11M | 53.30M | 55.50M | 49.78M | 46.84M |
| Total assets | 457.36M | 437.78M | 456.36M | 451.68M | 451.12M | 475.21M |
| Total current liabilities | 68.36M | 59.23M | 61.64M | 68.50M | 60.99M | 73.39M |
| Short-term debt | 3.56M | 5.10M | 5.31M | 5.87M | 6.10M | 6.18M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 107,392,000.00 | 101,208,000.00 | 102,582,000.00 | 107,494,000.00 | 98,752,000.00 | 109,807,000.00 |
| Total equity | 349.97M | 336.57M | 353.78M | 344.18M | 352.37M | 365.40M |
| Retained earnings | -121.79M | -138.60M | -129.72M | -148.02M | -142.82M | -134.76M |
Cash flow
| Line item | 2018 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 12.77M | 25.80M | 20.95M | 43.96M | 35.72M | 14.59M | 15.73M | -34.23M |
| Depreciation & amortization | 2.46M | 3.70M | 3.10M | 3.64M | 4.51M | 5.12M | 6.89M | 8.73M |
| Free cash flow | 10.52M | 15.62M | 12.55M | 30.32M | 17.61M | -3.59M | -7.67M | -40.05M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 72.10M | 2.00K | 1.00K | 1.00K | 1.00K | -2.10M | -1.50M | -7.98M |
| Ending cash balance | 104.00M | 119.97M | 152.45M | 199.71M | 86.48M | 183.04M | 144.16M | 153.15M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Operating cash flow | -5.73M | -27.25M | 2.67M | -3.91M | -21.70M | 19.69M |
| Depreciation & amortization | 2.39M | 2.12M | 1.80M | 2.42M | 2.21M | 3.34M |
| Free cash flow | -7.20M | -29.04M | 1.78M | -5.59M | -22.14M | 19.20M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -1.28M | -4.55M | -1.98M | -164.00K | -1.87M | -2.73M |
| Ending cash balance | 173.11M | 167.13M | 176.16M | 153.15M | 131.86M | 148.58M |
Returns & efficiency
| Line item | 2018 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 5.67 | 9.61 | 3.31 | 10.75 | 13.12 | 5.95 | -5.16 | -21.70 |
| ROA %i | 4.22 | 7.51 | 2.55 | 8.12 | 10.19 | 4.72 | -4.05 | -16.74 |
| ROIC %i | 5.31 | 9.15 | 3.04 | 9.83 | 11.85 | 5.44 | -5.74 | -20.75 |
| 5-year avg ROE %i | -13.13 | -7.77 | -3.66 | 5.07 | 8.80 | 8.85 | 5.90 | 0.89 |
| EBIT margin %i | 5.32 | 7.89 | 4.14 | 14.47 | 15.40 | 8.71 | -4.02 | -19.19 |
| FCF / sales %i | 8.49 | 10.40 | 7.68 | 13.15 | 6.19 | -- | -- | -- |
| Current ratioi | 5.47 | 5.07 | 5.25 | 5.56 | 6.03 | 5.62 | 5.23 | 4.55 |
| Quick ratioi | 4.75 | 4.42 | 4.64 | 5.05 | 5.37 | 4.90 | 4.41 | 3.53 |
| Debt / assetsi | 3.19 | 4.60 | 4.20 | 9.27 | 7.41 | 7.33 | 7.60 | 8.49 |
| LT debt / equityi | 0.35 | 2.78 | 3.33 | 11.08 | 8.14 | 8.15 | 8.76 | 9.44 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 17.14 | 22.14 | 21.73 | 22.97 | 23.72 | 25.41 | 10.85 | -5.57 |
| Net income CAGR (3Y) %i | -- | -- | -- | 76.92 | 41.34 | 53.41 | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | 90.78 | 42.30 | 4.08 | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| ROE %i | -19.14 | -25.55 | -24.65 | -21.70 | -5.99 | 1.09 |
| ROA %i | -14.97 | -20.05 | -19.39 | -16.74 | -4.63 | 0.84 |
| ROIC %i | -17.44 | -24.52 | -23.26 | -20.75 | -5.42 | 0.41 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -16.15 | -36.39 | -27.29 | -19.19 | 2.13 | 12.08 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.78 | 4.94 | 5.21 | 4.55 | 5.12 | 4.66 |
| Quick ratioi | 3.88 | 3.83 | 4.16 | 3.53 | 4.09 | 3.86 |
| Debt / assetsi | 8.02 | 9.26 | 8.57 | 8.49 | 8.27 | 7.56 |
| LT debt / equityi | 9.46 | 10.52 | 9.55 | 9.44 | 8.85 | 8.15 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Ophthalmic surgical product segment100.00%
Quote time 2026-10-08 10:10:08 · For reference only, not investment advice and not tailored to your situation.